182 related articles for article (PubMed ID: 21174093)
1. Survival after intratumoral interleukin-2 treatment of 72 melanoma patients and response upon the first chemotherapy during follow-up.
Weide B; Eigentler TK; Pflugfelder A; Leiter U; Meier F; Bauer J; Schmidt D; Radny P; Pföhler C; Garbe C
Cancer Immunol Immunother; 2011 Apr; 60(4):487-93. PubMed ID: 21174093
[TBL] [Abstract][Full Text] [Related]
2. High response rate after intratumoral treatment with interleukin-2: results from a phase 2 study in 51 patients with metastasized melanoma.
Weide B; Derhovanessian E; Pflugfelder A; Eigentler TK; Radny P; Zelba H; Pföhler C; Pawelec G; Garbe C
Cancer; 2010 Sep; 116(17):4139-46. PubMed ID: 20564107
[TBL] [Abstract][Full Text] [Related]
3. A phase 2 trial of sequential temozolomide chemotherapy followed by high-dose interleukin 2 immunotherapy for metastatic melanoma.
Tarhini AA; Kirkwood JM; Gooding WE; Moschos S; Agarwala SS
Cancer; 2008 Oct; 113(7):1632-40. PubMed ID: 18720480
[TBL] [Abstract][Full Text] [Related]
4. Treatment of metastatic melanoma with combined chemotherapy containing cisplatin, vinblastine and dacarbazine (CVD) and biotherapy using interleukin-2 and interferon-alpha.
Legha SS; Ring S; Bedikian A; Plager C; Eton O; Buzaid AC; Papadopoulos N
Ann Oncol; 1996 Oct; 7(8):827-35. PubMed ID: 8922197
[TBL] [Abstract][Full Text] [Related]
5. A phase II study of biochemotherapy for advanced melanoma incorporating temozolomide, decrescendo interleukin-2 and GM-CSF.
Lewis KD; Gibbs P; O'Day S; Richards J; Weber J; Anderson C; Zeng C; Baron A; Russ P; Gonzalez R
Cancer Invest; 2005; 23(4):303-8. PubMed ID: 16100942
[TBL] [Abstract][Full Text] [Related]
6. Metastatic melanoma: a regional review and future directions.
Khan KH; Goody RB; Hameed H; Jalil A; Coyle VM; McAleer JJ
Tumori; 2012; 98(5):575-80. PubMed ID: 23235751
[TBL] [Abstract][Full Text] [Related]
7. A phase I study of intratumoral ipilimumab and interleukin-2 in patients with advanced melanoma.
Ray A; Williams MA; Meek SM; Bowen RC; Grossmann KF; Andtbacka RH; Bowles TL; Hyngstrom JR; Leachman SA; Grossman D; Bowen GM; Holmen SL; VanBrocklin MW; Suneja G; Khong HT
Oncotarget; 2016 Sep; 7(39):64390-64399. PubMed ID: 27391442
[TBL] [Abstract][Full Text] [Related]
8. Intralesional treatment of stage III metastatic melanoma patients with L19-IL2 results in sustained clinical and systemic immunologic responses.
Weide B; Eigentler TK; Pflugfelder A; Zelba H; Martens A; Pawelec G; Giovannoni L; Ruffini PA; Elia G; Neri D; Gutzmer R; Becker JC; Garbe C
Cancer Immunol Res; 2014 Jul; 2(7):668-78. PubMed ID: 24906352
[TBL] [Abstract][Full Text] [Related]
9. Phase II trial of dacarbazine and thalidomide for the treatment of metastatic melanoma.
Ott PA; Chang JL; Oratz R; Jones A; Farrell K; Muggia F; Pavlick AC
Chemotherapy; 2009; 55(4):221-7. PubMed ID: 19451711
[TBL] [Abstract][Full Text] [Related]
10. Clinicopathological characteristics, diagnosis and treatment of melanoma in Serbia--the Melanoma Focus Study.
Kandolf-Sekulović L; Babović N; Jokić N; Nikolin B; Nikolić D; Janjić Z; Mijugković Z; Rajović M; Novaković M; Pejcić I; Kovaević P; Mihajlović D; Roganović T; Ferenc V; Nikolić J; Marinković M; Bizetić Z
Vojnosanit Pregl; 2015 Apr; 72(4):312-6. PubMed ID: 26040176
[TBL] [Abstract][Full Text] [Related]
11. Interleukin-2-based biochemotherapy for patients with stage IV melanoma: long-term survivors outside a clinical trial setting.
Hess V; Herrmann R; Veelken H; Schwabe M
Oncology; 2007; 73(1-2):33-40. PubMed ID: 18332650
[TBL] [Abstract][Full Text] [Related]
12. Dacarbazine, cisplatin, and interferon-alfa-2b with or without interleukin-2 in metastatic melanoma: a randomized phase III trial (18951) of the European Organisation for Research and Treatment of Cancer Melanoma Group.
Keilholz U; Punt CJ; Gore M; Kruit W; Patel P; Lienard D; Thomas J; Proebstle TM; Schmittel A; Schadendorf D; Velu T; Negrier S; Kleeberg U; Lehman F; Suciu S; Eggermont AM
J Clin Oncol; 2005 Sep; 23(27):6747-55. PubMed ID: 16170182
[TBL] [Abstract][Full Text] [Related]
13. Phase III comparison of vitespen, an autologous tumor-derived heat shock protein gp96 peptide complex vaccine, with physician's choice of treatment for stage IV melanoma: the C-100-21 Study Group.
Testori A; Richards J; Whitman E; Mann GB; Lutzky J; Camacho L; Parmiani G; Tosti G; Kirkwood JM; Hoos A; Yuh L; Gupta R; Srivastava PK;
J Clin Oncol; 2008 Feb; 26(6):955-62. PubMed ID: 18281670
[TBL] [Abstract][Full Text] [Related]
14. Phase II study of neoadjuvant concurrent biochemotherapy in melanoma patients with local-regional metastases.
Buzaid AC; Colome M; Bedikian A; Eton O; Legha SS; Papadopoulos N; Plager C; Ross M; Lee JE; Mansfield P; Rice J; Ring S; Lee JJ; Strom E; Benjamin R
Melanoma Res; 1998 Dec; 8(6):549-56. PubMed ID: 9918417
[TBL] [Abstract][Full Text] [Related]
15. Durable complete responses with high-dose bolus interleukin-2 in patients with metastatic melanoma who have experienced progression after biochemotherapy.
Tarhini AA; Kirkwood JM; Gooding WE; Cai C; Agarwala SS
J Clin Oncol; 2007 Sep; 25(25):3802-7. PubMed ID: 17761969
[TBL] [Abstract][Full Text] [Related]
16. Phase II trial of intralesional therapy with interleukin-2 in soft-tissue melanoma metastases.
Radny P; Caroli UM; Bauer J; Paul T; Schlegel C; Eigentler TK; Weide B; Schwarz M; Garbe C
Br J Cancer; 2003 Nov; 89(9):1620-6. PubMed ID: 14583759
[TBL] [Abstract][Full Text] [Related]
17. Overall and progression-free survival in metastatic melanoma: analysis of a single-institution database.
Khan MA; Andrews S; Ismail-Khan R; Munster PN; Brem S; King J; Reintgen DS; Sondak VK; Daud AI
Cancer Control; 2006 Jul; 13(3):211-7. PubMed ID: 16885917
[TBL] [Abstract][Full Text] [Related]
18. Phase II trial of subcutaneous interleukin-2, subcutaneous interferon-alpha, intravenous combination chemotherapy, and oral tamoxifen in the treatment of metastatic melanoma: final results of cancer biotherapy research group 94-11.
Dillman RO; Soori G; Wiemann MC; Schulof R; Dobbs TW; Ruben RH; DePriest CB; Church C
Cancer Biother Radiopharm; 2000 Oct; 15(5):487-94. PubMed ID: 11155820
[TBL] [Abstract][Full Text] [Related]
19. Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial.
Eggermont AMM; Blank CU; Mandalà M; Long GV; Atkinson VG; Dalle S; Haydon AM; Meshcheryakov A; Khattak A; Carlino MS; Sandhu S; Larkin J; Puig S; Ascierto PA; Rutkowski P; Schadendorf D; Koornstra R; Hernandez-Aya L; Di Giacomo AM; van den Eertwegh AJM; Grob JJ; Gutzmer R; Jamal R; Lorigan PC; van Akkooi ACJ; Krepler C; Ibrahim N; Marreaud S; Kicinski M; Suciu S; Robert C;
Lancet Oncol; 2021 May; 22(5):643-654. PubMed ID: 33857412
[TBL] [Abstract][Full Text] [Related]
20. Does complete response to systemic therapy in patients with stage IV melanoma translate into long-term survival?
Bedikian AY; Johnson MM; Warneke CL; Papadopoulos NE; Kim KB; Hwu WJ; McIntyre S; Rohlfs M; Homsi J; Hwu P
Melanoma Res; 2011 Feb; 21(1):84-90. PubMed ID: 21102360
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
